• Retatrutide


  • CasNo:2381089-83-2
  • Purity:99%

Product Details;

CasNo: 2381089-83-2

Competitve 2381089-83-2 with wholesale price and Fast Delivery

  • Molecular Formula:-
  • Molecular Weight:-
  • Appearance/Colour:-
  • PKA:-
  • PSA:-
  • LogP:-

Retatrutide (Cas 2381089-83-2) Usage


Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors.

2381089-83-2 Relevant articles

Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?

Sheila A Doggrell

, Expert Opinion on Investigational Drugs Volume 32, 2023 - Issue 5

Although retatrutide may be superior to the GLP-1 receptor agonist dulaglutide in reducing plasma glucose and body weight, this is not a meaningful comparison, as another GLP-1 receptor agonist (semaglutide) is more potent than dulaglutide at this and may have similar efficacy to retatrutide. Retatrutide also needs to be compared to another Eli Lilly and Company drug, the combined GLP-1 and GIP receptor agonist, tirzepatide.

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

Ania M. Jastreboff, M.D., Ph.D., Lee M. Kaplan, M.D., Ph.D., Juan P. Frías, M.D., Qiwei Wu, Ph.D., Yu Du, Ph.D., Sirel Gurbuz, M.D., Tamer Coskun, M.D., Ph.D., Axel Haupt, M.D., Ph.D., Zvonko Milicevic, M.D., and Mark L. Hartman, M.D. for the Retatrutide Phase 2 Obesity Trial Investigators*

, N Engl J Med 2023; 389:514-526

The least-squares mean percentage change in body weight at 24 weeks in the retatrutide groups was −7.2% in the 1-mg group, −12.9% in the combined 4-mg group, −17.3% in the combined 8-mg group, and −17.5% in the 12-mg group, as compared with −1.6% in the placebo group.